Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 8Prostatic Neoplasms 7Carcinoma, Non-Small-Cell Lung 3Urogenital Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Prostate Adenocarcinoma 1Neoplasms, Radiation-Induced 1Melanoma 1Lymphatic Metastasis 1Lung Neoplasms 1Locally Advanced Lung Carcinoma 1Glioma 1Genital Neoplasms, Male 1Financial Stress 1Diffuse Intrinsic Pontine Glioma 1Deception 1Carcinoma, Merkel Cell 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Cancer 1

Interventions

Nivolumab 13Surveys and Questionnaires 6Ipilimumab 6linrodostat 5Standard of Care 5Paclitaxel 5Bevacizumab 5Sirolimus 4Pemetrexed 4Interviews as Topic 4Gemcitabine 4Docetaxel 4ARRY-334543 4temsirolimus 3relatlimab 3Erlotinib Hydrochloride 3Cetuximab 3Carboplatin 3regorafenib 2anlotinib 2abemaciclib 2Vorinostat 2Trastuzumab 2Sorafenib 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2Magnetic Resonance Spectroscopy 2Doxorubicin 2Dasatinib 2Cyclophosphamide 2vorolanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Cancer × Radiation Dose Hypofractionation × Clear all
NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡